PureTech Health PLC
LSE:PRTC

Watchlist Manager
PureTech Health PLC Logo
PureTech Health PLC
LSE:PRTC
Watchlist
Price: 154.6 GBX -3.25% Market Closed
Market Cap: 370.1m GBX
Have any thoughts about
PureTech Health PLC?
Write Note

PureTech Health PLC
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

PureTech Health PLC
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
PureTech Health PLC
LSE:PRTC
Other Long-Term Assets
$879k
CAGR 3-Years
N/A
CAGR 5-Years
2%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Other Long-Term Assets
$8.3B
CAGR 3-Years
20%
CAGR 5-Years
44%
CAGR 10-Years
26%
Gilead Sciences Inc
NASDAQ:GILD
Other Long-Term Assets
$7.2B
CAGR 3-Years
15%
CAGR 5-Years
10%
CAGR 10-Years
23%
Amgen Inc
NASDAQ:AMGN
Other Long-Term Assets
$10.4B
CAGR 3-Years
18%
CAGR 5-Years
43%
CAGR 10-Years
21%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Long-Term Assets
$3.2B
CAGR 3-Years
49%
CAGR 5-Years
17%
CAGR 10-Years
95%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Long-Term Assets
$4.1B
CAGR 3-Years
70%
CAGR 5-Years
34%
CAGR 10-Years
31%
No Stocks Found

PureTech Health PLC
Glance View

Market Cap
370.1m GBX
Industry
Biotechnology

PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The company is headquartered in Boston, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2015-06-19. The firm is engaged in discovering, developing and commercializing medicines for diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The firm's wholly owned pipeline consists of six therapeutic candidates including LYT-100 (deupirfenidone), LYT-200, LYT-210, LYT-300 (oral allopregnanolone), LYT-500, and LYT-503/IMB-150. Its segments include Internal, Controlled Founded Entity, Non-Controlled Founded Entities, and Parent Company and Other. Its Internal segment is advancing wholly owned programs designed to harness immunological, fibrotic and lymphatic system mechanisms. These classes of immunomodulatory drugs are designed to treat serious diseases, including lung dysfunction, immuno-oncology, lymphatic, neurological and neuropsychological disorders.

PRTC Intrinsic Value
37.96 GBX
Overvaluation 75%
Intrinsic Value
Price

See Also

What is PureTech Health PLC's Other Long-Term Assets?
Other Long-Term Assets
879k USD

Based on the financial report for Dec 31, 2023, PureTech Health PLC's Other Long-Term Assets amounts to 879k USD.

What is PureTech Health PLC's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
2%

Over the last year, the Other Long-Term Assets growth was 7 891%.

Back to Top